Trial will investigate OBT076 as monotherapy and in sequence with balstilimab CD205, OBT076’s target antigen, is overexpressed in ~ 80 % of ACC tumor biopsy samples Recurrent or metastatic ACC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results